The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Topic summary

About the Receptor biology category

This is a generated summary. It shows the 5 most-liked posts from a topic of 11, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
OB
owen.bradyTL4 Moderator5 Jun 2026#1
Community wiki post. Any member at trust level 3 or above can edit this post; every edit is recorded. Last edited by owen.brady on 6 Jun 2026.
  • 6 Jun 2026 — owen.brady: Initial wiki conversion.
Editors: owen.brady, mira.patel, hana.sato
Staff post. Actions described here are recorded in the public moderation log and may be challenged in Meta.

GLP-1, GIP, glucagon and amylin receptor signalling, bias, desensitisation and central versus peripheral action.

This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author and a note. If the scope described here has drifted from what actually gets posted, edit it rather than starting a topic about it.

What belongs here

  • Questions specific to receptor biology, with the units and the context stated.
  • Reports and datasets, with the collection method stated.
  • Disagreement about the substance, conducted in public.

What belongs elsewhere

  • Anything urgent belongs in Safety, immediately, and not here.
  • Anything about how this site works belongs in Meta.
  • Requests for a maintained page belong in Wiki requests.

Before posting, it is worth checking the documentation commons and this category's tag pages. A great deal of what gets asked here has a maintained answer with a review date on it, which is more reliable than a two-year-old reply.

16 likes 2mo
I
IsaksenTL3Regular18 Jun 2026#4

Suggestion for the wiki post above: it would be worth linking the two or three most-referenced topics in this category directly, since new members reliably ask for exactly those. Happy to make the edit myself if nobody objects, with a revision note.

20 likes 1mo
HB
h.brandtTL2 Moderator27 Jun 2026#7

Cross-reactivity and selectivity: the compounds are not perfectly selective for their target receptors. Semaglutide has some activity on other receptors; tirzepatide activates both GLP-1 and GIP with different affinities. The off-target effects are part of the overall pharmacology.

28 likes 1mo
RV
r.venkatesanTL3Wiki editor30 Jun 2026#8
Isaksen, post #4: Suggestion for the wiki post above: it would be worth linking the two or three most-referenced topics in this category directly, since new members reliably ask for exactly those. Happy to make the edit myself if nobody objects, with a revision note. Go to post

Central versus peripheral action: GLP-1 agonism works through both central nervous system effects (appetite) and peripheral effects (gastric motility, insulin). The balance is not fully characterised.

14 likes in reply to #4 28d
FK
f.kimaniTL2 Moderator7 Jul 2026#11

Glucagon receptor agonism: glucagon receptor agonism increases energy expenditure and promotes hepatic fat oxidation. The mechanism is distinct from GLP-1 and GIP agonism and the clinical consequences are still being characterised.

29 likes 20d

Read the full topic (11 posts)

Suggested topics

TopicParticipantsRepliesViewsActivity
Amylin receptor signalling and satiety — what changed since
On the subject in the title: Amylin receptor signalling and satiety — what changed since Working notes rather than a conclusion. A documentation question rather than an analytical one. I have a certificate in…
GCCNRCBPB+73 78 3.5k 2mo
Glucagon receptor agonism in a weight-loss compound
On the subject in the title: Glucagon receptor agonism in a weight-loss compound Working notes rather than a conclusion. Posting the method first, because I know what the first three replies will otherwise…
OBLMJM 2 5.1k 20mo
Amylin receptor signalling and satiety
Amylin receptor signalling and satiety Writing it up because I had to work it out twice and would rather nobody else did. A documentation question rather than an analytical one. I have a certificate in front…
SGBCTNNATT+22 26 1.8k 9mo
Vagal afferents and the gut-brain pathway
On the subject in the title: Vagal afferents and the gut-brain pathway Working notes rather than a conclusion. A documentation question rather than an analytical one. I have a certificate in front of me that…
KRBSKSBCD+5 9 44k 13mo
Receptor desensitisation as a tolerance hypothesis, and its weak evidence
Receptor desensitisation as a tolerance hypothesis, and its weak evidence — setting out what I have, and where I think it stops being reliable. A documentation question rather than an analytical one. I have a…
MAVSOVSKMP+52 57 25k just now

Related topics — sharing the tags amylin analogues, semaglutide, tirzepatide

TopicParticipantsRepliesViewsActivity
How the published trials escalated, tabulated side by side
The question in the title: How the published trials escalated, tabulated side by side I will give what I have already checked below so nobody repeats it. A question about technique rather than about dose. I…
ASCTGAOFCC+4 8 4.2k 5mo
Second pass at: Semaglutide and alcohol: what is actually documented
Second pass at: Semaglutide and alcohol: what is actually documented Writing it up because I had to work it out twice and would rather nobody else did. I have seen STEP 1 ( N Engl J Med , 2021) cited in…
IBDNOFID+15 19 4.4k 13mo
Micro-titration: a disputed topic, argued properly
Micro-titration: a disputed topic, argued properly Writing it up because I had to work it out twice and would rather nobody else did. A question about technique rather than about dose. I have been doing the…
ESKHVKASNP+99 110 61k 2d
Follow-up: Why appetite effects are mostly central
Asking directly, because I could not find a straight answer: Why appetite effects are mostly central A documentation question rather than an analytical one. I have a certificate in front of me that reports a…
CRRWMHKMN+86 90 61k 9mo
Revisiting: Is there a ceiling dose beyond which semaglutide stops adding benefit?
Revisiting: Is there a ceiling dose beyond which semaglutide stops adding benefit? — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURMOUNT-4 ( JAMA ,…
AWBWCEPLEK+5 9 30k 8d